ライフサイエンスコーパス: metabolic syndrome

1 ion is associated with the increased risk of metabolic syndrome.

2 herapeutic implications for the treatment of metabolic syndrome.

3 ral diseases, especially type-2 diabetes and metabolic syndrome.

4 iated with an increased risk of diabetes and metabolic syndrome.

5 or for developing hypertension, diabetes, or metabolic syndrome.

6 ue of shizukaol F as a possible treatment of metabolic syndrome.

7 luded class II obesity, type 2 diabetes, and metabolic syndrome.

8 for dyslipidaemia, and 18.6% (18.2-19.0) for metabolic syndrome.

9 s, and death in CHB patients with or without metabolic syndrome.

10 ted with mitochondrial toxicity, asthma, and metabolic syndrome.

11 it is also closely linked to obesity and the metabolic syndrome.

12 ticularly in the contexts of obesity and the metabolic syndrome.

13 on for adiponectin formation in diet-induced metabolic syndrome.

14 oxidative stress, inflammatory mediators and metabolic syndrome.

15 than 2.5 and absence of any component of the metabolic syndrome.

16 ndividuals and used time-dependent status of metabolic syndrome.

17 mon feature of type 2 diabetes, obesity, and metabolic syndrome.

18 ble therapeutic target for the management of metabolic syndrome.

19 self and may explain aspects of drug-induced metabolic syndrome.

20 it may be beneficial in type II diabetes and metabolic syndrome.

21 ogenesis of obesity, insulin resistance, and metabolic syndrome.

22 MIR122, might be developed for treatment of metabolic syndrome.

23 lness and death in the world, as well as the metabolic syndrome.

24 easingly recognized clinical complication of metabolic syndrome.

25 ne and improving metabolic parameters in the metabolic syndrome.

26 that could be relevant to conditions such as metabolic syndrome.

27 c steatosis, a precursor or manifestation of metabolic syndrome.

28 f adiponectin and protects from diet-induced metabolic syndrome.

29 are at high risk of physical inactivity and metabolic syndrome.

30 Adiponectin protects against metabolic syndrome.

31 advanced pediatric NAFLD and features of the metabolic syndrome.

32 s in humans are associated with diabetes and metabolic syndrome.

33 r risk factors that are clustered within the metabolic syndrome.

34 .4 +/- 6.3 kPa, and 188 patients (12.8%) had metabolic syndrome.

35 y associated with insulin resistance and the metabolic syndrome.

36 ence is now a criterion for the diagnosis of metabolic syndrome.

37 ning response in adipose tissue to treat the metabolic syndrome.

38 e inflammation in the context of obesity and metabolic syndrome.

39 ulum (ER) stress elicits EC dysregulation in metabolic syndrome.

40 d as a susceptibility locus for diabetes and metabolic syndrome.

41 s adiposity and the associated parameters of metabolic syndrome.

42 but do not have findings consistent with the metabolic syndrome.

43 nge of solutes and water under conditions of metabolic syndrome.

44 strategies for the treatment of obesity and metabolic syndrome.

45 biota as bioeffectors of message, leading to metabolic syndrome.

46 d profiles, may affect visceral fat mass and metabolic syndrome.

47 in diet-induced obese mice with pre-existing metabolic syndrome.

48 g therapeutic approach to reduce obesity and metabolic syndrome.

49 a encroachment and protected against LGI and metabolic syndrome.

50 rlying causes and progression of obesity and metabolic syndrome.

51 D-dependent obesity and hallmark features of metabolic syndrome.

52 he ability to reverse visceral adiposity and metabolic syndrome.

53 possible confounding factors, including the metabolic syndrome.

54 roachment, low-grade inflammation (LGI), and metabolic syndrome.

55 nct from NAFLD occurring as a consequence of metabolic syndrome.

56 reported to be individually mutated in human metabolic syndromes.

57 lude partial lipodystrophies associated with metabolic syndromes.

58 ith B-mode ultrasonography, body mass index, metabolic syndrome, 10-year cardiovascular disease risk

59 olic blood pressure and the incidence of the metabolic syndrome, (2) determine the potential mediatin

60 ertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05).

61 he increased incidence and prevalence of the metabolic syndrome, a clinical condition characterized b

62 Metabolic syndrome, a cluster of 3 or more risk factors

63 Patients with the metabolic syndrome, a major risk factor for diabetes, ma

64 Metabolic syndrome, abdominal obesity and dyslipidaemia,

65 p'-DDE -treatment exacerbated several of the metabolic syndrome-accompanying features induced by high

66 e criteria of the metabolic syndrome (MetS) [metabolic syndrome according to Adult Treatment Panel II

67 atment Panel III criteria present (MetS+) or metabolic syndrome according to Adult Treatment Panel II

68 Whether metabolic syndrome affects the long-term prognosis of CH

69 Skeletal muscle biopsies from humans with metabolic syndrome after 12 weeks of oral sodium nitrite

70 europathy as a function of the components of metabolic syndrome after adjusting for demographic facto

71 th development of hypertension, diabetes, or metabolic syndrome after adjustment for sex, baseline ag

72 Metabolic syndrome also associates with impaired nerve f

73 college completion is associated with higher metabolic syndrome among black and Hispanic young adults

74 sed prevalence of selected components of the metabolic syndrome among Hispanic/Latina women in the US

75 were 1.60 (95% CI 1.30-1.96; P < 0.001) for metabolic syndrome and 1.37 (1.03-1.82; P = 0.021) for t

76 with complications of obesity, including the metabolic syndrome and atherosclerosis.

77 Ortality RISk (AMORIS) (n = 528,580) and the Metabolic syndrome and Cancer project (Me-Can) cohorts (

78 promising target for treatment of diabetes, metabolic syndrome and cancer, but few GLUT5 inhibitors

79 ted with increases in comorbidities, such as metabolic syndrome and cardiovascular diseases.

80 However, the temporal relation between metabolic syndrome and declining thyroid function remain

81 lyses for the relation between components of metabolic syndrome and declining thyroid function were a

82 tal-placental unit in mice in the absence of metabolic syndrome and determined the association betwee

83 advances on how metabolic disorders such as metabolic syndrome and diabetes mellitus change channel

84 and lipotoxicity, which are hallmarks of the metabolic syndrome and diabetes.

85 gher DMA% was associated with higher risk of metabolic syndrome and diabetes.

86 The association between metabolic syndrome and DNA methylation is of great resea

87 a therapeutic approach for treatment of the metabolic syndrome and dyslipidemia, while avoiding syst

88 Individuals with metabolic syndrome and frank type 2 diabetes are at incr

89 Our findings for metabolic syndrome and high fasting blood glucose remain

90 Hepatocyte steatosis is a component of metabolic syndrome and insulin resistance.

91 is a common disease closely associated with metabolic syndrome and insulin resistance.

92 Metabolic syndrome and its components-abdominal obesity,

93 .5), and temperature with the development of metabolic syndrome and its components.

94 .Fatty liver is one of the major features of metabolic syndrome and its development is associated wit

95 e associations of diabetes, pre-diabetes and metabolic syndrome and its separate components with poly

96 FLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular ca

97 These studies validate a rodent model of metabolic syndrome and PH-HFpEF, suggesting a potential

98 st studies have shown an association between metabolic syndrome and polyneuropathy, but the precise c

99 d not only to cognitive impairment, but also metabolic syndrome and psychiatric illness including dep

100 ation between subclinical hypothyroidism and metabolic syndrome and selected components.

101 ecommended level on physiological markers of metabolic syndrome and the hepatic transcriptome.

102 atenin signaling pathway are linked with the metabolic syndrome and type 2 diabetes in humans, the me

103 ongly associated with the risk of developing metabolic syndrome and type 2 diabetes in the general po

104 sociations were only partly explained by the metabolic syndrome and visceral adiposity, suggesting a

105 Additionally, body mass index, metabolic syndrome, and aortic (18)F-fluorodeoxyglucose

106 ith an important role in insulin resistance, metabolic syndrome, and AT inflammation.

107 m, other metabolic parameters related to the metabolic syndrome, and atherosclerosis.

108 hich carries the risk of developing obesity, metabolic syndrome, and cardiovascular diseases.

109 Advanced age, features of the metabolic syndrome, and chronic heart and lung disease w

110 ry heart disease (any/premature), absence of metabolic syndrome, and healthy lifestyle were compared

111 g the development of cardiovascular disease, metabolic syndrome, and immune dysfunction.

112 diposity indicated by WtHR of 0.5 or higher, metabolic syndrome, and increased BMI.

113 ic system, such as inflammation, obesity and metabolic syndrome, and inflammatory bowel disease.

114 potential new treatment for type 2 diabetes, metabolic syndrome, and other human diseases modulated b

115 th cardiovascular disease, diabetes, and the metabolic syndrome, and recent efforts have begun to elu

116 Body mass index, metabolic syndrome, and SAT were not predictive of CVD e

117 iotensin system (RAS) is associated with the metabolic syndrome, and the new onset of type 2 diabetes

118 ted the potential association among obesity, metabolic syndrome, and TNBC in African American women a

119 pack-years of smoking, all components of the metabolic syndrome, and visceral adiposity attenuated cr

120 t of human disorders, in particular, cancer, metabolic syndromes, and autoimmune diseases.

121 tant role in many diseases, such as cancers, metabolic syndromes, and neurodegenerative disorders.

122 ty paradox," "metabolically healthy obese," "metabolic syndrome," and beneficial role of lifestyle me

123 Obesity, insulin resistance and the metabolic syndrome are associated with changes to the gu

124 Individuals with metabolic syndrome are at a greater risk for developing

125 Although obesity and metabolic syndrome are considered to have a strong assoc

126 Metabolic syndrome as defined by the International Diabe

127 ce were protected against the development of metabolic syndrome as evident from a markedly lower weig

128 Exposures: Components of metabolic syndrome (as defined by the National Cholester

129 bolic diseases such as obesity, diabetes, or metabolic syndrome, as well as liver-specific disorders

130 Moreover, various markers of the metabolic syndrome, as well as peroxide stress, were act

131 In participants without polyneuropathy, metabolic syndrome associated with lower sural sensory n

132 ribute to the pathology of asthma, but limit metabolic syndrome associated with obesity.

133 ate the efficacy and mechanism of nitrite in metabolic syndrome associated with PH-HFpEF, we develope

134 0), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.

135 he non-digested and digested samples towards metabolic syndrome-associated enzymes (alpha-amylase, al

136 ovide for superior outcomes in subjects with metabolic syndrome-associated PVD.

137 Eighteen patients had metabolic syndrome at baseline.

138 FpEF model in rats with multiple features of metabolic syndrome attributable to double-leptin recepto

139 raction was confirmed in the cross-sectional Metabolic Syndrome Berlin Potsdam study (p = 0.012), wit

140 t nitrite improves two key components of the metabolic syndrome, blood pressure and insulin sensitivi

141 KEY POINTS: With the development of the metabolic syndrome, both post-capillary and collecting v

142 with altered gut microbiota composition and metabolic syndrome, both present in many cases of colore

143 eutic potential for treating obesity and the metabolic syndrome by increasing energy expenditure.

144 Thus, fermentable fiber protects against metabolic syndrome by nourishing microbiota to restore I

145 Cancer cachexia is a devastating metabolic syndrome characterized by systemic inflammatio

146 ildren with moderate to severe psoriasis had metabolic syndrome compared with 1 of 38 children with m

147 her in participants who began the study with metabolic syndrome compared with metabolically normal co

148 tions of drinkers had obesity, diabetes, and metabolic syndrome compared with nondrinkers (P < .01).

149 n 10 years with psoriasis were found to have metabolic syndrome compared with none of 29 in the contr

150 Metabolic syndrome components were defined according to

151 The number of positive metabolic syndrome conditions was also associated with e

152 is strongly associated with obesity and the metabolic syndrome, conditions that cause lipid accumula

153 These clinical complications include metabolic syndrome, consisting of systemic arterial hype

154 Hyperphagia, obesity, or metabolic syndrome could have produced this previously u

155 low at successive arteriolar bifurcations in metabolic syndrome creates an environment where a large

156 lic risk factors, referred to as cardiorenal metabolic syndrome (CRMS), is increasingly recognized as

157 Metabolic syndrome defines a cluster of interrelated ris

158 To shed light on the etiology of metabolic syndrome development, it is important to under

159 have significant comorbidities (eg, obesity, metabolic syndrome, diabetes, and arthritis) and increas

160 Prevalence of insulin resistance and metabolic syndrome did not differ significantly among th

161 NASH) because one third of patients with the metabolic syndrome die of liver disease.

162 ipates in the development and progression of metabolic syndrome disorders such as obesity, glucose in

163 ntation from diseased patients or mice (IBD, metabolic syndrome, etc.) to germ-free mice was found to

164 particles increases the risk of obesity and metabolic syndrome: findings from a natural experiment i

165 College completion is associated with lower metabolic syndrome for whites across all levels of child

166 ; for women, OR = 1.19, 95% CI: 1.05, 1.35), metabolic syndrome (for men, OR = 1.31, 95% CI: 1.21, 1.

167 Patients with metabolic syndrome had higher cumulative probability of

168 Metabolic syndrome has become a major public health chal

169 While research into vascular outcomes of the metabolic syndrome has focused on arterial/arteriolar an

170 Patients with metabolic syndrome have a greater risk of cardiovascular

171 Diseases of the liver related to metabolic syndrome have emerged as the most common and u

172 associated with a higher risk of developing metabolic syndrome (hazard ratio (HR) = 1.27, 95% confid

173 ot differentially influence visceral fat and metabolic syndrome in a low-processed, lower-glycemic di

174 nces); and had at least one component of the metabolic syndrome in addition to hypertension.

175 ns action is associated with features of the metabolic syndrome in animal models and humans.

176 edisposition towards an early development of metabolic syndrome in ca. 25% of healthy male individual

177 On depletion of Vps15, the metabolic syndrome in genetic and diet-induced models of

178 in 531 well-phenotyped Finnish men from the Metabolic Syndrome In Men (METSIM) study.

179 25) for this allele in the population-based Metabolic Syndrome in Men (METSIM)study and invited thes

180 rtal inflammation, hepatic fibrosis, and the metabolic syndrome in pediatric NAFLD.

181 eduction in the percentage of diagnosed with metabolic syndrome in the brief group, but they had fewe

182 of NAFLD parallels high rates of obesity and metabolic syndrome in this age group, with unhealthy lif

183 of childhood disadvantage for depression and metabolic syndrome in young adulthood, across race/ethni

184 ggested to contribute to several features of metabolic syndrome including insulin resistance, but to

185 digestion inhibited enzymes associated with metabolic syndrome, including alpha-amylase, alpha-gluco

186 digestion inhibited enzymes associated with metabolic syndrome, including alpha-glucosidase, amylase

187 Systemically, the metabolic syndrome, including dyslipidemia and insulin r

188 is D is associated with many features of the metabolic syndrome, including non-alcoholic fatty liver

189 mproves human health with protection against metabolic syndromes, including type 2 diabetes; however,

190 Metabolic syndrome increased the risk of cardiovascular

191 del to investigate the association between a metabolic syndrome index and DNA methylation in the Norm

192 The progressive relation among metabolic syndrome, insulin resistance (IR), and dementi

193 ons associated with PCOS, including obesity, metabolic syndrome, IR, cardiovascular diseases, and inf

194 Metabolic syndrome is an independent risk factor of live

195 Metabolic syndrome is characterized by insulin resistanc

196 Molecular basis of this metabolic syndrome is not yet completely understood.

197 cle venular function with development of the metabolic syndrome, issues such as aggregate microvascul

198 vere metabolic disorders, including obesity, metabolic syndrome, lipodystrophy, and cachexia.

199 is associated with predictors related to the metabolic syndrome, liver iron content is mainly associa

200 the metabolic disturbances that comprise the metabolic syndrome may play a role in the development or

201 teria (CAF) diet fed rats, a robust model of metabolic syndrome (MeS), were administered 1000mg/kg of

202 rom healthy controls (n = 13), subjects with metabolic syndrome (MetS) (n = 13), and diabetic hemodia

203 valuated with the use of the criteria of the metabolic syndrome (MetS) [metabolic syndrome according

204 The association of the metabolic syndrome (MetS) and component cardiovascular r

205 density lipoproteins (VLDL) is a hallmark of metabolic syndrome (MetS) and each manifestation of MetS

206 tic protein-9(BMP-9) levels in subjects with Metabolic Syndrome (MetS) and examine the relationship b

207 Metabolic syndrome (MetS) and Type 2 diabetes mellitus (

208 sulin in childhood and their impact on adult metabolic syndrome (MetS) and type 2 diabetes mellitus (

209 Although dichotomous criteria for the metabolic syndrome (MetS) appear heritable, it is not kn

210 ve shown that cardiovascular disease and the metabolic syndrome (MetS) are associated with serum conc

211 Metabolic syndrome (MetS) doubles the risk of adverse ca

212 Few studies on the epidemic of metabolic syndrome (MetS) examined multi-ethnic adults i

213 Most previous studies on metabolic syndrome (MetS) examined urban and high income

214 associated with multiple disorders including metabolic syndrome (MetS) features, though metabolomic m

215 Metabolic syndrome (MetS) has become a global public hea

216 Metabolic syndrome (MetS) has been associated with chron

217 Increased risk of developing metabolic syndrome (MetS) has been associated with the A

218 The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation tha

219 The Think Tank consensus was that the metabolic syndrome (MetS) is a complex pathophysiologica

220 Metabolic syndrome (MetS) is a major factor for the occu

221 Metabolic syndrome (MetS) is a multifactorial disease cl

222 Metabolic syndrome (MetS) is thought to influence severa

223 Metabolic markers associated with the Metabolic Syndrome (MetS) may be affected by interaction

224 at baseline in individuals with established metabolic syndrome (MetS) or diabetes identifies CHD and

225 ernal Areca catechu nut chewing on offspring metabolic syndrome (MetS) risk in humans, on obesity and

226 The associations of the metabolic syndrome (MetS) with intraocular pressure and

227 Metabolic syndrome (MetS), a complex cluster of cardiova

228 Metabolic syndrome (MetS), defined by a constellation of

229 tohepatitis, which is a manifestation of the metabolic syndrome (MetS).

230 on LDL cholesterol and risk factors for the metabolic syndrome (MetS).

231 unctions in twenty individuals with signs of metabolic syndrome (MetS).

232 ent of multifunctional ingredients targeting metabolic syndrome (MetS).

233 ased risk of developing various hallmarks of metabolic syndrome (MetS).

234 nce is a well-known risk factor for obesity, metabolic syndrome (MetSyn) and associated cardiovascula

235 ents and to examine the joint association of metabolic syndrome (MetSyn) in combination with obesity,

236 nd subcutaneous adipose tissue (SAT) area on metabolic syndrome (MS) has been debated.

237 The prevalence of metabolic syndrome (MS) varies worldwide due to genetic

238 LDL (ox-LDL) as a proxy, is associated with metabolic syndrome (MS), whether ox-LDL mediates the ass

239 Eligible women medically diagnosed with metabolic syndrome (n=115) were randomly assigned to one

240 The link with metabolic syndrome, obesity, and cardiac disease in the

241 The Nlrp3 inflammasome pathway mediated the metabolic syndrome of caspase-12-deficient mice as ablat

242 The impact of LSM and metabolic syndrome on hepatic events, cardiovascular eve

243 impact on cardiovascular events; neither did metabolic syndrome on hepatic events.

244 rols, while proportions of participants with metabolic syndrome or BMI-determined obesity were not si

245 In patients with metabolic syndrome or diabetes, circulating plasma ceram

246 so been described, such as the prevention of metabolic syndrome or type 2 diabetes.

247 5% confidence interval, 1.5-2.8) and overall metabolic syndrome (OR, 1.4; 95% confidence interval, 1.

248 bese mothers with PCOS and other features of metabolic syndrome (OR, 2.59; 95% CI, 1.02-6.58).

249 ia (OR: 1.15 for SAT; OR: 1.56 for VAT), and metabolic syndrome (OR: 1.43 for SAT; OR: 1.82 for VAT;

250 ly associated with a higher incidence of the metabolic syndrome (OR=2.49; 95% CI 1.30-4.77), a steepe

251 ess and risk for hypertension, diabetes, and metabolic syndrome over the course of 25 years among 199

252 s associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PD

253 contribution of PGE2 to other aspects of the metabolic syndrome, particularly abdominal adiposity, dy

254 ch their circulating levels are increased in metabolic syndrome patients.

255 a potential treatment, the pNaKtide, for the metabolic syndrome phenotype.

256 r lutein was associated with a lower risk of metabolic syndrome (pooled RR: 0.75; 95% CI: 0.60, 0.92)

257 umption is reported to benefit patients with metabolic syndrome, possibly due to improved adipose tis

258 This study's aim was to determine whether metabolic syndrome predicts tooth loss and worsening of

259 n to predispose to obesity and the so-called metabolic syndrome provides further biological support f

260 ansplant is a risk factor for posttransplant metabolic syndrome (PTMS), cardiovascular events, and re

261 a higher risk of posttransplant obesity and metabolic syndrome-related complications.

262 large reductions in the use of treatment of metabolic syndrome-related conditions, inhalants for obs

263 ustained decreases occurred for treatment of metabolic syndrome-related conditions, such as any gluco

264 likely to have increased WtHR, obesity, and metabolic syndrome relative to children without psoriasi

265 neuropathy, but the role of pre-diabetes and metabolic syndrome remains unclear.

266 en documented in neurodegenerative diseases, metabolic syndrome, renal disorders, skin disorders, and

267 ipants developed hypertension, diabetes, and metabolic syndrome, respectively.

268 Analysing separate components of metabolic syndrome revealed associations for elevated wa

269 Diabetes mellitus, hypertension, metabolic syndrome, smoking, hyperlipidemia, and a seden

270 etic dyslipidemia; clarifying a diagnosis of metabolic syndrome so it can be used to make lifestyle c

271 ticenter study using data from the Brazilian Metabolic Syndrome Study conducted from June 29, 2011, t

272 m the cohort of Beijing Child and Adolescent Metabolic Syndrome Study.

273 cells can modulate whole-body metabolism (in metabolic syndromes such as type 2 diabetes and obesity)

274 ted mice against high-fat diet (HFD)-induced metabolic syndrome, the effect was not significantly imp

275 re associated with alcohol, obesity, and the metabolic syndrome, their mechanisms of pathogenesis are

276 rophage IRE1alpha pathway drives obesity and metabolic syndrome through impairing BAT activity and WA

277 oids are known to promote the development of metabolic syndrome through the modulation of both feedin

278 1), reduced the percentage of diagnosed with metabolic syndrome to 81.6% (beta=-0.17, p=.003), and de

279 male mice could recapitulate aspects of the metabolic syndrome to understand the mechanistic basis f

280 ds special promise in imaging NASH and other metabolic syndromes, to monitor disease progression and

281 with prevalent insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipi

282 ividuals are more likely to develop obesity, metabolic syndrome, type II diabetes, and cardiovascular

283 e strains with differing susceptibilities to metabolic syndrome using diet and antibiotic treatment.

284 LSM >8.0 kPa but not metabolic syndrome was an independent risk factor of dea

285 Metabolic syndrome was associated with polyneuropathy (O

286 The prevalence of metabolic syndrome was comparable between cases (17%) an

287 Metabolic syndrome was diagnosed as per the criteria of

288 The association between parity and metabolic syndrome was examined among 7467 Hispanic/Lati

289 ess markers associated to the progression of Metabolic Syndrome was investigated.

290 ar (p=0.50), and in men, the proportion with metabolic syndrome was similar (p=0.07), and overweight

291 -defined role of PKCdelta in the etiology of metabolic syndrome, we present a novel PKCdelta signalin

292 Data on type 2 diabetes and components of metabolic syndrome were also collected.

293 controlling for risk factors, patients with metabolic syndrome were at a 21% excess risk of developi

294 hort of 66,822 participants with and without metabolic syndrome were followed.

295 NAFLD is associated with obesity and metabolic syndrome whereas ALD is associated with excess

296 of the association of insulin resistance and metabolic syndrome with acne in male patients is lacking

297 ulation are clinically obese and suffer from metabolic syndrome with an increased risk of postmenopau

298 te the association of specific components of metabolic syndrome with polyneuropathy.

299 characterized by muscle wasting, is a lethal metabolic syndrome with undefined etiology.

300 high-fat diet developed the core features of metabolic syndrome, with subsequent renal lipid accumula